SK287607B6 - Spôsob stanovenia zlúčenín vhodných na inhibíciu aktivity aspoň jednej karboanhydrázy a použitie uvedených zlúčenín ako liečiva na liečbu a/alebo prevenciu obezity - Google Patents

Spôsob stanovenia zlúčenín vhodných na inhibíciu aktivity aspoň jednej karboanhydrázy a použitie uvedených zlúčenín ako liečiva na liečbu a/alebo prevenciu obezity Download PDF

Info

Publication number
SK287607B6
SK287607B6 SK61-2003A SK612003A SK287607B6 SK 287607 B6 SK287607 B6 SK 287607B6 SK 612003 A SK612003 A SK 612003A SK 287607 B6 SK287607 B6 SK 287607B6
Authority
SK
Slovakia
Prior art keywords
compounds
obesity
treatment
prevention
identified
Prior art date
Application number
SK61-2003A
Other languages
English (en)
Slovak (sk)
Other versions
SK612003A3 (en
Inventor
Johannes Hebebrand
Jochen Antel
Ulf Preuschoff
Samuel David
Holger Sann
Michael Weske
Original Assignee
Solvay Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals Gmbh filed Critical Solvay Pharmaceuticals Gmbh
Publication of SK612003A3 publication Critical patent/SK612003A3/sk
Publication of SK287607B6 publication Critical patent/SK287607B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C12Q1/32—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase involving dehydrogenase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SK61-2003A 2000-07-20 2001-07-12 Spôsob stanovenia zlúčenín vhodných na inhibíciu aktivity aspoň jednej karboanhydrázy a použitie uvedených zlúčenín ako liečiva na liečbu a/alebo prevenciu obezity SK287607B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10035227A DE10035227A1 (de) 2000-07-20 2000-07-20 Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind
PCT/EP2001/008051 WO2002007821A1 (de) 2000-07-20 2001-07-12 Verfahren zum auffinden von verbindungen, welche zur behandlung und/oder prophylaxe von obesitas geeignet sind

Publications (2)

Publication Number Publication Date
SK612003A3 SK612003A3 (en) 2003-06-03
SK287607B6 true SK287607B6 (sk) 2011-03-04

Family

ID=7649538

Family Applications (1)

Application Number Title Priority Date Filing Date
SK61-2003A SK287607B6 (sk) 2000-07-20 2001-07-12 Spôsob stanovenia zlúčenín vhodných na inhibíciu aktivity aspoň jednej karboanhydrázy a použitie uvedených zlúčenín ako liečiva na liečbu a/alebo prevenciu obezity

Country Status (27)

Country Link
EP (1) EP1307262B1 (pl)
JP (1) JP2004504053A (pl)
KR (1) KR100818827B1 (pl)
CN (1) CN1443085B (pl)
AR (1) AR028730A1 (pl)
AT (1) ATE278441T1 (pl)
AU (2) AU2001277534B9 (pl)
BR (1) BR0112547A (pl)
CA (1) CA2416647A1 (pl)
CZ (1) CZ2003156A3 (pl)
DE (2) DE10035227A1 (pl)
DZ (1) DZ3393A1 (pl)
ES (1) ES2230346T3 (pl)
HK (1) HK1057499A1 (pl)
HU (1) HUP0302309A3 (pl)
IL (2) IL153971A0 (pl)
MX (1) MXPA02012907A (pl)
NO (1) NO20030233L (pl)
NZ (1) NZ523960A (pl)
PL (1) PL201165B1 (pl)
PT (1) PT1307262E (pl)
RU (1) RU2268721C2 (pl)
SK (1) SK287607B6 (pl)
TR (1) TR200402670T4 (pl)
TW (1) TWI274157B (pl)
UA (1) UA74588C2 (pl)
WO (1) WO2002007821A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1997370B (zh) 2004-05-19 2011-06-01 索尔瓦药物有限公司 N-氨磺酰-n＇-芳基哌嗪类化合物在制备用于预防或治疗肥胖和相关疾病的药物中的用途
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
KR20080012360A (ko) 2005-05-20 2008-02-11 얀센 파마슈티카 엔.브이. 설파미드 유도체의 제조 방법
AR057570A1 (es) 2005-11-14 2007-12-05 Solvay Pharm Gmbh Derivados de n-sulfamoil-n'-benzopiranopiperidinas espirocondensadas, composiciones farmaceuticas que los comprenden, un procedimiento para su preparacion y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por las isoenzimas anhidrasas carbonicas subtipos ii y/o
US8492431B2 (en) * 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
TW200812573A (en) 2006-05-19 2008-03-16 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
NO2106260T3 (pl) 2007-01-25 2018-05-05
US8809385B2 (en) 2008-06-23 2014-08-19 Janssen Pharmaceutica Nv Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
KR20150023405A (ko) * 2012-05-24 2015-03-05 베바 파마슈티칼스 엘티디 간 기능 개선 방법
CN106770611B (zh) * 2016-12-22 2019-01-29 广西师范大学 一种用于细胞原位检测小分子化合物进入线粒体的方法
RU2771430C1 (ru) * 2021-09-21 2022-05-04 Федеральное государственное бюджетное научное учреждение "Научный центр неврологии" (ФГБНУ НЦН) Способ количественного определения антиконвульсантов в плазме крови больных эпилепсией

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552897A (en) * 1983-02-01 1985-11-12 American Cyanamid Company Salts of 1-(aminodihalophenyl)-2-aminoethanols and antilipogenic compositions prepared therefrom
US6288095B1 (en) * 1987-09-04 2001-09-11 Beecham Group P.L.C. Compounds
US5126324A (en) * 1990-06-07 1992-06-30 Genentech, Inc. Method of enhancing growth in patients using combination therapy
JPH08502969A (ja) * 1992-10-29 1996-04-02 ジェネンテク，インコーポレイテッド 肥満の予防または治療方法
AU693478B2 (en) * 1994-11-10 1998-07-02 Metabolic Pharmaceuticals Limited Treatment of obesity
CA2258893C (en) * 1996-06-28 2005-06-14 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant sulfamate derivatives useful in treating obesity
US20030100594A1 (en) * 2001-08-10 2003-05-29 Pharmacia Corporation Carbonic anhydrase inhibitor

Also Published As

Publication number Publication date
HK1057499A1 (en) 2004-04-08
ATE278441T1 (de) 2004-10-15
RU2268721C2 (ru) 2006-01-27
PT1307262E (pt) 2004-12-31
EP1307262B1 (de) 2004-10-06
CN1443085A (zh) 2003-09-17
IL153971A (en) 2009-07-20
AU2001277534B9 (en) 2006-02-23
UA74588C2 (en) 2006-01-16
EP1307262A1 (de) 2003-05-07
AU7753401A (en) 2002-02-05
TWI274157B (en) 2007-02-21
CA2416647A1 (en) 2003-01-20
BR0112547A (pt) 2003-07-01
IL153971A0 (en) 2003-07-31
KR100818827B1 (ko) 2008-04-01
MXPA02012907A (es) 2003-09-22
AR028730A1 (es) 2003-05-21
HUP0302309A3 (en) 2005-06-28
PL201165B1 (pl) 2009-03-31
NO20030233D0 (no) 2003-01-17
NZ523960A (en) 2004-12-24
DE50104023D1 (de) 2004-11-11
DZ3393A1 (fr) 2002-01-31
SK612003A3 (en) 2003-06-03
AU2001277534B2 (en) 2005-09-29
WO2002007821A1 (de) 2002-01-31
NO20030233L (no) 2003-03-19
CN1443085B (zh) 2010-04-28
DE10035227A1 (de) 2002-01-31
PL363518A1 (pl) 2004-11-29
KR20030022284A (ko) 2003-03-15
JP2004504053A (ja) 2004-02-12
HUP0302309A2 (hu) 2003-11-28
TR200402670T4 (tr) 2004-11-22
ES2230346T3 (es) 2005-05-01
CZ2003156A3 (cs) 2003-06-18

Similar Documents

Publication Publication Date Title
SK287607B6 (sk) Spôsob stanovenia zlúčenín vhodných na inhibíciu aktivity aspoň jednej karboanhydrázy a použitie uvedených zlúčenín ako liečiva na liečbu a/alebo prevenciu obezity
US6946243B2 (en) Method of identifying compounds suitable for treatment and/or prophylaxis of obesity
Johnson et al. Why has butyrylcholinesterase been retained? Structural and functional diversification in a duplicated gene
US6511800B1 (en) Methods of treating nitric oxide and cytokine mediated disorders
Saha et al. Lipid abnormalities in tissues of the KKAy mouse: effects of pioglitazone on malonyl-CoA and diacylglycerol
Benoit et al. Loss of quinone reductase 2 function selectively facilitates learning behaviors
Koechling et al. Effects of 3-amino-1, 2, 4-triazole on brain catalase in the mediation of ethanol consumption in mice
Medvedev et al. Renalase, a new secretory enzyme responsible for selective degradation of catecholamines: achievements and unsolved problems
JP2002511850A (ja) 報酬欠損症候群の対立遺伝子多遺伝子診断および処置
Ryan et al. Isolation and characterization of cells resistant to ML236B (compactin) with increased levels of 3-hydroxy-3-methylglutaryl coenzyme A reductase.
Reilly et al. A peroxisomal acyltransferase in mouse identifies a novel pathway for taurine conjugation of fatty acids
Miyajima et al. Molecular characterization of gene expression in human lactate dehydrogenase‐A deficiency
Takabe et al. Gene expression induced by BO-653, probucol and BHQ in human endothelial cells
Kosel et al. In vitro metabolism of citalopram by monoamine oxidase B in human blood
ZA200300444B (en) Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity.
Redila et al. Effects of ethanol on an acetaldehyde drug discrimination with a conditioned taste aversion procedure
Lee et al. Rat malonyl-CoA decarboxylase; cloning, expression in E. coli and its biochemical characterization
KR20110054880A (ko) 알콜해독 및 숙취해소용 해양심층수 함유 키토산올리고당
Sandler et al. Tyramine and depressive illness
Chen et al. Lower micromolar activity of the antifungal imidazoles on the bacterial-type bifunctional aldehyde/alcohol dehydrogenase (AdhE) in Cryptosporidium parvum and in vitro efficacy against the zoonotic parasite
SONONE EFFECT OF THE DRUG IMIPRAMINE ON ENZYMES OF RAT BRAIN

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20120712